Brief: SkinBioTherapeutics Appoints Rachel Parsonage As CEO & Alyson Levett As Chair On Permanent Basis
22/09/2026 08:11
BRIEF-SkinBioTherapeutics Appoints Rachel Parsonage As CEO & Alyson Levett As Chair On Permanent Basis Sept 22 (Reuters) - SkinBioTherapeutics PLC SBTX.L:
SKINBIOTHERAPEUTICS - TRADING STATEMENT
SKINBIOTHERAPEUTICS - APPOINTS RACHEL PARSONAGE AS CEO AND ALYSON LEVETT AS CHAIR ON PERMANENT BASIS
SKINBIOTHERAPEUTICS - ALYSON LEVETT TO BECOME PERMANENT NON-EXECUTIVE CHAIR OF BOARD
SKINBIOTHERAPEUTICS - EXPECTS FY26 REVENUE GROWTH OF 20.5% TO £4.70 MILLION
SKINBIOTHERAPEUTICS PLC: TRADING IN EARLY MONTHS OF FY27 HAS BEEN AHEAD OF MANAGEMENT'S INTERNAL EXPECTATIONS
SKINBIOTHERAPEUTICS - EXPECTS FY26 ADJUSTED EBITDA LOSS OF £1.60 MILLION, BEFORE EXCEPTIONAL COSTS OF £1.20 MILLION
Source text: ID:nRSV6644Va
Further company coverage: SBTX.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skinbiotherapeutics
See all newsBrief: SkinBioTherapeutics Appoints Rachel Parsonage As CEO & Alyson Levett As Chair On Permanent Basis
SkinBioTherapeutics - Trading Statement
Brief: SkinBioTherapeutics Appoints Anita Slater To Start As Interim CFO
SkinBioTherapeutics - Appointment of Interim CFO
SkinBioTherapeutics - Holding(s) in Company